Skip to main content

Advertisement

SpringerLink
Log in

The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

There are no data regarding the late toxicity of trastuzumab (T) administration with radiotherapy (RT). In this experimental study, we aimed to asses if concurrent or sequential administration of T has any impact for the development of radiation-induced pulmonary fibrosis in rats. Fifty-four female Wistar-albino rats were divided into 6 groups. First group of rats (Group 1; concurrent T) had irradiation to whole thoracic region concurrently with T. Second group (Group 2: sequential T–RT) received thoracic irradiation, 1 week after T. Third group (Group 3: sequential RT–T) had thoracic irradiation first and they had T injection 1 week after RT. Fourth group (Group 4: T only) had only T application. Fifth group (Group 5: RT) had only RT. The last group (Group 6: sham) of rats were observed without any application. A single dose of 12 Gy was given to both lungs with an anterior field at 2 cm depth. T dose which was equivalent to 6 mg/kg adult dose was calculated for each rat, and injected by the tail vein. As an end point the extent of pulmonary fibrosis for each field was graded on a scale from 0 (normal lung or minimal fibrous thickening) to 4 (total fibrous obliteration of the field) at histopathological examination. The mean value of fibrosis scores were 1.44, 1.77, 1.75 and 1.62 for Group 1, 2, 3 and 5, respectively, without any statistically significant differences among them (P > 0.05). The mean value of fibrosis scores for Group 4 and 6 were 0.25 and 0.33, respectively (P > 0.05). When the mean value of fibrosis scores of the groups which had RT with or without T, compared with the observation and the T only groups, the difference was significant (P < 0.05) (one-way ANOVA and Tukey HSD post hoc tests) As a conclusion: addition of T to thoracic irradiation either sequentially or concomitantly did not increase radiation-induced pulmonary fibrosis in rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.

    Article  CAS  PubMed  Google Scholar 

  2. Belkacémi Y, et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol. 2008;19:1110–6.

    Article  PubMed  Google Scholar 

  3. Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.

    Article  CAS  PubMed  Google Scholar 

  4. Piccart-Gebhart MJ, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.

    Article  CAS  PubMed  Google Scholar 

  5. Smith I, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36.

    Article  CAS  PubMed  Google Scholar 

  6. Joensuu H, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;23(354):809–20.

    Article  Google Scholar 

  7. Whelan T, Darby S, Taylor S, McGale P, Ewertz M. 2006 update of the early breast cancer trialists’ collaborative group overview of radiation therapy for early breast cancer. ASCO Educational Booklet. 2007;3:6.

    Google Scholar 

  8. Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.

    Article  PubMed  Google Scholar 

  9. Pietras RJ, et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999;59:1347–55.

    CAS  PubMed  Google Scholar 

  10. Raben S, et al. Comparison of acute breast and chest wall toxicity in women treated with external beam radiation with and without concurrent herceptin in a community cancer center. Int J Radiat Oncol Biol Phys. 2006;66(Suppl. 1):S541–2.

    Google Scholar 

  11. Bellon JR, Gover MT, Burstein HJ, Harris JR, Harris LN. Concurrent Trastuzumab and radiation therapy in the adjuvant treatment of breast cancer. Int J Radiat Oncol Biol Phys. 2005;63(Suppl. 1):S55–6.

    Google Scholar 

  12. Halyard MY, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009;27:2638–44.

    Article  CAS  PubMed  Google Scholar 

  13. Horton JK et al. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with Trastuzumab: a phase II Trial. Int J Radiat Oncol Biol Phys. 2009 Jun 26. [Epub ahead of print].

  14. Bese NS, et al. The effects of tamoxifen on radiation-induced pulmonary fibrosis in Wistar albino rats: results of an experimental study. Breast. 2006;15:456–60.

    Article  PubMed  Google Scholar 

  15. Pegram M, Ngo D. Application and potential limitations if animal models utilized in the development of trastuzumab: a case study advanced drug delivery reviews. Adv Drug Deliv Rev. 2006;58:732–4.

    Article  CAS  Google Scholar 

  16. Ward HE, Kemsley L, Davies L, Holecek M, Berend N. The pulmonary response to sublethal thoracic irradiation in the rat. Radiat Res. 1993;136:15–21.

    Article  CAS  PubMed  Google Scholar 

  17. Ashcroft T, Simpson JM. Timbrell V: simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467–70.

    Article  CAS  PubMed  Google Scholar 

  18. Daniel WW. Biostatistics: a foundation for analysis in the health sciences. 6th ed. New York: Wiley; 1995. p. 273–312.

    Google Scholar 

  19. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002;105:1551–4.

    Article  CAS  PubMed  Google Scholar 

  20. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  CAS  PubMed  Google Scholar 

  21. Suter TM, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859–65.

    Article  CAS  PubMed  Google Scholar 

  22. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14:14–24.

    Article  CAS  PubMed  Google Scholar 

  23. Shaffer R, Tyldesley S, Rolles M, Chia S, Mohamed I. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol. 2009;90:122–6.

    Article  CAS  PubMed  Google Scholar 

  24. Stone HB, et al. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003;4:529–36.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest notification

There are no declared conflicts of interest concerning this manuscript.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Cerrahpasa Medical School, Istanbul University, 34098, Cerrahpasa, Istanbul, Turkey

    N. S. Bese, C. Umay & A. Ober

  2. Department of Medical Oncology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey

    S. Serdengecti

  3. Department of Pathology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey

    N. Kepil

  4. Department of Experimental Animal Breeding and Research Laboratory, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey

    T. Altug

  5. Department of Biostatistics, Medical School, Trakya University, Edirne, Turkey

    N. Sut

Authors
  1. N. S. Bese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Umay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Serdengecti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Kepil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Sut
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Altug
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Ober
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. S. Bese.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bese, N.S., Umay, C., Serdengecti, S. et al. The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study. Med Oncol 27, 1415–1419 (2010). https://doi.org/10.1007/s12032-009-9395-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9395-5

Keywords

Search

Navigation